SamYang Foods Q3 Operating Profit Rises 49.9% Year-on-Year
Bitget2026/11/06 06:56- SamYang Foods’ third-quarter 2026 operating profit rose 49.9% year over year to KRW 196.2 billion.
- Revenue increased 25.3% from a year earlier to KRW 791.8 billion.
- Net income fell 18.9% year over year to KRW 89.2 billion.
- Compared with the previous quarter, operating profit increased 11.3%, while net income declined 35.1%.
- Operating profit for January-September 2026 reached KRW 549.5 billion, up 42.7% from a year earlier.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
The US FDA requires semaglutide, tirzepatide, and other GLP-1 drugs to include new warnings about the risk of eye disease.
NAION is an eye disease that can cause sudden, painless loss of vision, with some patients potentially experiencing permanent visual impairment. The drugs involved include products from Eli Lilly and Novo Nordisk. According to analysts at Citi, the incidence of NAION is relatively low, and given the significant benefits of GLP-1 drugs in weight control and blood sugar management, the actual impact on prescription behavior is expected to be limited. On Monday, the stock prices of Eli Lilly and Novo Nordisk increased, with the news not causing any significant impact on their share prices.
CleanSpark presents fully funded Sandersville project in investor presentation
Forge Nano completes acquisition of HzO
Crypto prices
More
